LAC Med Berhad (5341.KL) - Deep Dive Research Report

Sector: Health Care Equipment & Services | Exchange: Bursa Malaysia Main Market | FYE: 31 December Report date: 20 September 2026

A note on sources before we begin

LAC Med listed on the Main Market of Bursa Malaysia on 10 December 2025. It is nine months old as a public company. It does not hold earnings conference calls, and no transcripts exist for it - this is normal for a Bursa-listed company of this size, where the quarterly report, the accompanying press release and occasional media interviews are the entire management communication channel.

The six-concall requirement therefore cannot be met literally. Working out the reporting calendar first: with a 31 December year-end and quarterly reporting, the most recent results should be Q2 FY2026 (quarter ended 30 June 2026), due by 31 August 2026. That release landed on 19 August 2026. Q3 FY2026 is not due until 30 November 2026, so Q2 FY2026 is correctly the latest period. The MoatMap database block confirms the same.

In place of six concalls, this report uses the six management communication events since the IPO process began, all verified:

Plus a CEO interview in The Star on 14 September 2026, six days before this report. Section 9 is written against this set, and I say plainly where the track record is simply too short to judge.

1. What the company does

LAC Med sells other people's medical machines to Malaysian and Indonesian hospitals, and then makes its living from everything that has to happen around those machines.

That sentence is deliberately unglamorous, because the business is unglamorous and the money is in the unglamorous part. LAC Med does not manufacture anything. It is an authorised distributor for eleven international brands - Philips, Samsung, Stryker, Abbott, Bayer, LG Electronics, Baxter (Hill-Rom), Epson, Alpinion, plus the AI software vendors annalise.ai and AIRS Medical (SwiftMR). It buys their equipment, and sells it into Malaysian hospitals.

The reason a hospital pays LAC Med rather than buying direct from Philips is that an MRI machine is not a product you can ship in a box. Consider what actually happens when a Malaysian private hospital decides it wants a 3-Tesla MRI.

The machine weighs several tonnes and contains a superconducting magnet cooled by liquid helium. It cannot go in an ordinary room. The room needs a radiofrequency-shielded cage so the scanner does not pick up the hospital's own electrical noise. It needs a quench pipe to vent helium to the outside if the magnet fails. It needs floor loading calculations, a dedicated power supply, chilled water, and an access route that frequently means removing a wall. For a CT scanner or an angiography suite, add lead shielding to a specified thickness and a licence from Malaysia's Atomic Energy Licensing Board (AELB), because those machines emit ionising radiation and are regulated as radiation sources, not as furniture.

So what the hospital is actually buying is a project: site survey, structural and shielding design, coordination with the building contractor, procurement and import, installation, calibration, commissioning, regulatory sign-off, radiographer training, then a service contract for the next seven to ten years, then the consumables and contrast media that flow through the machine every day of its life.

LAC Med does all of that. That is the whole proposition, and it is why the company describes itself as being in "supply and integration" rather than in sales.

The founding story, and why the ICT DNA matters

The origin explains more than it usually does. Per the FY2025 annual report, Liew Yoon Kit (49), now Non-Independent Non-Executive Chairman, co-founded Glocomp in 1999 and LAC Medical in 2003, and has over twenty years of experience in the ICT industry. He holds a Bachelor of Arts in Geography from the University of Malaya. Chan Yue Mun (62), now a Non-Independent Non-Executive Director, also co-founded Glocomp with Liew Yoon Kit; the annual report records a banking and finance career from 1983, including roles at Chase Manhattan Bank and Asia Commercial Finance.

Glocomp is an ICT infrastructure business. LAC Medical was founded four years later by people whose professional formation was in enterprise computing, not in medicine. That is the single most useful fact about this company's strategic direction, and it shows up everywhere: in the decision to buy a healthcare software company (GoCloud Solutions), in the PACS contract with KPJ Healthcare, in the AI imaging distributorships, and in the framing of the whole group as a "healthcare technology" business rather than a medical equipment dealer.

Liew Yoon Poh (46), brother of the Chairman, is Group Chief Executive Officer, appointed 22 November 2024 (the incorporation date of the listed holding company). Per the annual report he has over twenty years in business development and healthcare distribution and was previously Managing Director of the operating business; he holds a Diploma and a Bachelor of Science in Economics from the University of London. He signed the June 2024 agreement with Sunway Medical Centre and annalise.ai as Managing Director of LAC Medical Supplies (Bernama, 10 June 2024).

The fourth substantial shareholder, Giam Teck Eng, is not on the board. The annual report identifies him as a substantial shareholder only, and I could not source a biography for him from the filings I was able to read, so none is offered here.

What the business used to be, and what it is becoming

Until 2023 LAC Med carried two brands. Philips (distributorship since 2017) and Samsung (since 2013) between them accounted for 56.7% to 69.6% and 20.3% to 36.9% of group revenue respectively across FY2022 to FY2024 - together somewhere between 80.4% and 93.6% of everything the company sold (Tradeview IPO note, 24 Nov 2025). That is not a diversified distributor. That is a Philips-and-Samsung agency with a service arm attached.

Since 2023 the portfolio has gone from two brands to eleven, and the company has added three genuinely new business models: Equipment-as-a-Service (EaaS), Medical Equipment Asset Management Services (MEAMS), and software subscriptions. The IPO was raised explicitly to fund that transition.

The reason for the urgency is visible in one prospectus disclosure that deserves to be read twice:

Non-recurring revenue contributes between 97.8% and 98.3% of total revenue.

Nearly every ringgit LAC Med earned before the IPO had to be won again the following year. A distributor with a 2,587-unit installed base across Malaysia's hospital system and essentially no annuity is a business that has been leaving its best asset unmonetised. Everything management is currently doing - EaaS, MEAMS, PACS subscriptions, consumables, reagents - is an attempt to fix exactly that.

The core value proposition

For a private hospital: single point of accountability across the capital project, plus a service network that keeps utilisation up. An idle CT scanner is a direct revenue hole, so uptime is the product.

For a public hospital or concessionaire: a prequalified bidder with AELB and Medical Device Authority licences, a track record across Ministry of Health tenders, and the balance sheet to carry a four-year supply contract.

For a brand owner like Philips or Samsung: market access into a country with 373 hospitals and 800-plus clinics without building a local field-engineering organisation. LAC Med reports 58% coverage of Malaysian hospitals - 217 of 373 - and over 300 active customer accounts (The Edge, Dec 2025).

That third relationship is the one that determines whether this company exists in ten years, and Section 8 treats it accordingly.

2. Business segments

LAC Med reports three revenue segments. The split is not arbitrary - it maps precisely onto how much physical infrastructure work a product requires, which in turn determines the margin, the working capital and the competitive set.

Source: FY2025 Annual Report; FY2024 mix from the IPO factsheet.

2.1 Supply and Integration of Medical Devices (64% of FY2025 revenue)

What it does. This is the turnkey project business: fixed, infrastructure-dependent imaging equipment. MRI systems, CT scanners, angiography suites, fluoroscopy systems - the machines that need a purpose-built room. LAC Med takes the job from site survey through structural and shielding design, power and cooling provisioning, import and logistics, installation, calibration, regulatory commissioning, staff training and handover, then holds the maintenance contract afterwards.

The core capability. Two things, and neither is the equipment. First, project execution against a live hospital. The room being converted usually sits inside a functioning facility. The work is sequenced around clinical operations, coordinated with the hospital's own builder, and gated by AELB inspection before a single patient can be scanned. Getting that wrong does not produce a late delivery; it produces a radiology department that cannot bill. The Tradeview note characterises the barrier as "crisis management competency and a strong technical network," which is an unglamorous but accurate description of what twenty years of doing this actually buys.

Second, regulatory carry. An establishment licence from the Medical Device Authority under the Medical Device Act 2012, and AELB licensing for every ionising-radiation installation. These are not one-time hurdles - they are continuing obligations attached to each installed machine, and they are the reason a hospital cannot simply import a CT scanner from a cheaper source and self-install.

Why it is a separate segment. The economics are genuinely different. This is the lowest gross margin of the three by a wide distance - roughly two-fifths of what the related-products segment earns. It is also the most working-capital hungry: revenue is recognised over the project, which produces contract assets rather than cash. The FY2025 annual report shows contract assets exploding to RM49.9m at 31 December 2025, a more-than-fifteen-fold increase, which is the direct accounting footprint of this segment growing 48.6% in a single year.

Competitive position. Here LAC Med competes against the brand owners' own direct subsidiaries - Siemens Healthineers Malaysia, GE HealthCare Malaysia, Canon Medical, Fujifilm - and against Transmedic, the regional ASEAN distributor owned by EBOS Group. It wins on installed-base familiarity and on being the incumbent service provider for machines already in the building. It loses when a principal decides to go direct on a flagship account, or when a hospital group standardises on a brand LAC Med does not carry.

How it fits. This is the revenue engine and the order-book machine. Almost all of the RM246.9m order book sits here. It is not the margin engine, and management does not pretend it is.

2.2 Supply of Medical Equipment (24% of FY2025 revenue)

What it does. Standalone, plug-and-play devices that need no building work: ultrasound systems, mobile and portable X-ray units, diagnostic displays, patient monitoring devices. A hospital orders it, LAC Med delivers it, installs it in an afternoon, trains the operator, and services it.

The core capability. Volume distribution reach and clinical application support. Ultrasound in particular is a sonographer-driven purchase - the buyer is the person who will hold the probe, and they choose on image quality, workflow ergonomics and how well the applications specialist trains the department. LAC Med's 46% share of the Malaysian ultrasound machine market (independent market research by Vital Factor Consulting, cited in the IPO factsheet) is the single most striking competitive number in this company's disclosure, and it was built on Samsung (2013) and Philips (2017) ultrasound.

Why it is separate. No infrastructure work means no project risk, no contract assets, shorter cash conversion, and a gross margin roughly two and a half times the integration segment's. Different sales motion, different buyer, different balance sheet profile.

Competitive position. Strongest position the group holds. Against a 46% ultrasound share, the comparable figures are 11% in MRI and 6% in radiographic equipment - so the company is a genuine leader in one product category and a mid-tier participant in the others. Competitors here are Medi-Life (M) Sdn Bhd, which distributes ultrasound, X-ray and dental equipment, Antah Healthcare Group, and the principals' own channels.

How it fits. The margin ballast. It declined 40.4% in FY2025 - the reason the group's overall revenue mix shifted so hard toward integration - and that decline is the most important unexplained item in the FY2025 numbers. A sustained contraction here dilutes group profitability even while revenue grows.

2.3 Supply of Related Products and Services (12% of FY2025 revenue)

What it does. Everything recurring. Medical consumables and accessories; pathology reagents; contrast media for the Bayer injection systems; software licences and subscriptions including PACS; after-sales maintenance and service contracts; and the two new models, MEAMS and EaaS.

The core capability. Installed base plus software. LAC Med has put roughly 2,600 units of medical equipment into Malaysian healthcare facilities. Every one is a potential service contract, consumables account and software endpoint. The capability being built is the ability to convert that base into a subscription, which is precisely the discipline a group founded by ICT people ought to have.

Why it is separate. It is the highest gross margin of the three, by a very wide distance - roughly three times the integration segment. It is also the only genuinely recurring revenue in the group. It grew 61.2% in FY2025, the fastest of the three, off a small base.

Competitive position. Fragmented and contested. Consumables and reagents attract everyone including UMediC Group and BCM Alliance. Software is a different fight: the KPJ PACS win pits LAC Med against enterprise imaging vendors and health-IT integrators rather than device distributors.

How it fits. This is the strategic bet, and management says so. RM8m of IPO proceeds were earmarked for EaaS and MEAMS development. The entire investment case, as articulated at listing, is that this segment's share of the mix keeps rising.

Segment summary

3. Products and business detail

The brand portfolio

The company went from two brands to eleven between 2023 and listing. What each one contributes:

GE Healthcare was a former principal; that distributorship expired in 2019 and is no longer part of the portfolio.

Note the deliberate architecture in the post-2023 additions. Bayer contrast media, LG displays, Abbott reagents and AIRS Medical's software all attach to machines LAC Med has already installed. This is not a random broadening of the catalogue - it is an attempt to raise revenue per installed unit without winning a single new hospital.

How the delivery process actually works

For an integration project:

1. Tender or direct enquiry. Public hospital work arrives via Ministry of Health tenders, usually routed through a hospital support services concessionaire. Private work comes direct from the hospital's capital committee.
2. Site survey and design. Structural loading, access route, shielding specification, power, chilled water, quench routing for MRI.
3. Bid. Priced as a project, not a product. LAC Med's disclosed historical tender success rate is 25% to 30%.
4. Award and import. Equipment is ordered from the principal, shipped, cleared. This is where FX exposure is created - the purchase is in foreign currency, the contract is in ringgit.
5. Build. Room conversion, shielding installation, coordination with the hospital's contractor.
6. Install and commission. Machine assembly, calibration, phantom testing.
7. Regulatory sign-off. AELB licensing for radiation-emitting equipment; MDA compliance throughout.
8. Training and handover. Radiographers and radiologists trained on the specific system.
9. Service contract. Typically runs for the machine's economic life.
10. Consumables flow. Contrast media, reagents, accessories - for years.

Steps 9 and 10 are where the recurring-revenue strategy lives. Steps 1 through 8 are where the revenue is, and where almost all the risk sits.

The instrument placement model is the important variant, and it is what the Kedah contract runs on. LAC Med places diagnostic instruments in the hospital at no upfront charge, and is paid through the recurring supply of reagents and consumables over the contract term. The hospital converts capital expenditure into operating expenditure; LAC Med converts a one-time sale into a four-year annuity but funds the equipment itself. It is the consumables-razor model applied to pathology, and it is a materially different balance-sheet proposition from selling a machine.

Equipment-as-a-Service (EaaS) extends the same logic to imaging. Per the Tradeview IPO note, the mechanics are: LAC Med finances the equipment through bank borrowings at roughly 4% to 6%, then leases it to the hospital bundled with software, maintenance and support, targeting approximately a 10% IRR per product. The CEO was careful to distinguish this from leasing:

"Leasing is purely a financing mechanism. Under our model, we go on a risk-sharing, outcome-based partnership."

• Liew Yoon Poh, The Edge, December 2025

EaaS billing began in September 2025 and was described at listing as under 5% of revenue.

MEAMS (Medical Equipment Asset Management Services) is the GoCloud Solutions layer: IoT integration, real-time GPS tracking of mobile assets, predictive maintenance analytics and cloud-based asset management across a hospital's equipment fleet. It is aimed at Malaysia's healthcare digitalisation targets - clinics by 2027 and hospitals by 2029.

Group structure

The three operating subsidiaries were acquired into the listed holding company in September 2025 as part of the IPO restructuring.

Geographies

Malaysia is effectively the whole business. Coverage reaches 217 of 373 hospitals (58%) and over 800 clinics, with revenue concentrated in the central region around Klang Valley, and smaller positions in the northern, southern, east coast and East Malaysia regions. Roughly 2,600 units are installed across the customer base. The company employs approximately 85 people - a genuinely lean organisation for that footprint, which tells you how much of the physical work is subcontracted and how much of the value sits in coordination rather than labour.

Indonesia is a deliberate, slow build. PT Fairmed was incorporated in December 2024, began operations in July 2025 from a rented Jakarta office with about 20 staff, and holds an exclusive Alpinion ultrasound distributorship covering an existing 800-unit installed base - which means it starts with a service and consumables opportunity rather than from zero. Branch offices are planned for Sumatra, Surabaya and Kalimantan across 2026-2027, funded from the RM8m IPO allocation. The prize is scale: Indonesia has 2,710 general hospitals, 518 specialised hospitals and over 20,600 private clinics, against Malaysia's 373 hospitals.

The CEO's framing at listing was notably unhurried:

"a long-term build rather than a fast grab"

• Liew Yoon Poh, The Edge, December 2025

Milestones that changed the business

• 2003 - LAC Medical founded by Liew Yoon Kit, four years after he co-founded ICT firm Glocomp.
• 2013 - Samsung distributorship. The first anchor brand.
• 2017 - Philips distributorship. Becomes the dominant revenue contributor.
• 2019 - GE Healthcare distributorship expires. Concentration on two brands intensifies.
• 2023 - Brand expansion programme begins. Two brands become eleven over roughly two years.
• June 2024 - annalise.ai AI radiology deployment with Sunway Medical Centre. First AI software deal.
• December 2024 - PT Fairmed incorporated in Indonesia.
• 26 August 2025 - KPJ Healthcare enterprise PACS contract: a multi-year, subscription-based Philips enterprise imaging platform across 30 hospitals, with full implementation targeted within 24 months. The single largest recurring-revenue win in the company's history.
• September 2025 - EaaS billing commences.
• 10 December 2025 - Main Market listing at RM0.75.
• 15 June 2026 - Kedah pathology contract commences, running to 14 June 2030.

4. Customers

Who buys

The prospectus anonymises the largest accounts, describing them as a hospital support services concessionaire, a healthcare services provider, a listed specialist hospital operator and a university hospital. Publicly named customers include IHH Healthcare Group, Sunway Healthcare Group, Columbia Asia, MAHSA Hospital and KPJ Healthcare (Borneo Post, 10 Dec 2025; Bernama, June 2024).

By customer type in FY2024:

• Private healthcare institutions - 53.6%
• Medical device suppliers - 28.7%
• Concessionaire companies - 12.6%
• Other - approximately 5%

That second line is worth pausing on. Nearly 29% of revenue went to other medical device suppliers rather than to end users. LAC Med acts in part as a wholesaler to the trade - reselling brands it holds rights to, to smaller distributors who do not. It is real revenue but it is intermediated, lower-touch, and carries none of the installed-base stickiness that the hospital-direct business does.

Who makes the decision, and on what

Private hospital capital equipment. The requester is the head of radiology or cardiology. The approver is a capital committee, typically involving the CEO and CFO, and for a group like KPJ or IHH, a group-level procurement function. Criteria: clinical image quality, throughput per day, total cost of ownership over seven to ten years, service response time, and whether it integrates with the PACS and hospital information system already in place. Sales cycles run from a few months for ultrasound to well over a year for an MRI suite that requires building work.

Public hospital procurement. Routed through the Ministry of Health, usually via a hospital support services concessionaire that holds the regional contract. The criteria are formal and price-weighted, with prequalification on licensing, technical specification compliance, local service capability and track record. This is a tender process, and the 25-30% historical win rate is the honest measure of how contested it is.

Consumables and reagents. Decided by the laboratory or radiology department head, frequently locked in at the moment the instrument is placed. This is the whole point of instrument placement - the reagent decision is made years before the reagents are bought.

Software and PACS. Chief Medical Information Officer or IT director, with radiology leadership. Longest cycle of all, and the most consequential, because it is a platform decision.

Why they choose LAC Med

Four specific reasons, not generic ones:

1. Incumbency on the installed machine. With roughly 2,600 units in the field, LAC Med is frequently already the service provider. The replacement decision for an existing machine defaults heavily toward the incumbent.
2. The licences. MDA establishment licensing and AELB radiation licensing are non-trivial, and most hospitals do not want to manage them.
3. Single accountability on a project. When an MRI installation goes wrong, the hospital wants one phone number, not a dispute between an importer, a builder and a service agent.
4. Breadth across the capital and operating cycle. Eleven brands means LAC Med can bid on a wider share of a hospital's equipment list, and then supply the consumables.

Switching costs - honestly calibrated

They vary enormously by segment, and it is a mistake to average them.

High and real in the integration segment. A PACS platform, once deployed across 30 hospitals and integrated with a patient-facing application, is a decade-long decision - ripping it out means migrating years of imaging archives and retraining every radiologist. Similarly, an instrument placed under a four-year reagent contract locks the consumable stream for the term. Machine-level service contracts are sticky because the field engineers are trained on that specific system.

Low in the equipment supply segment. An ultrasound machine is a replacement purchase every five to seven years with essentially no infrastructure lock-in. The 46% share is a share of ongoing wins, not a captive base.

Effectively zero in the wholesale-to-trade channel. That is price-driven business.

Concentration - the honest read

The prospectus disclosed material customer concentration without publishing the percentages, and one independent IPO commentary estimated the top five customers at around 68% of revenue (LCHIPO IPO analysis, Nov 2025). Directionally that is consistent with a business where 53.6% goes to private healthcare institutions in a market with a handful of large hospital groups.

Is this a risk or a reflection of quality? Both, but the balance is uncomfortable. Malaysia's private hospital sector genuinely is concentrated - IHH, KPJ, Sunway and Columbia Asia are most of it - so a supplier with 58% hospital coverage will necessarily look concentrated. But concentration cuts hardest in a business where 97.8% to 98.3% of revenue was non-recurring. When a large customer defers a capital cycle, there is no annuity underneath to absorb the gap. The recurring-revenue strategy is, among other things, a concentration-risk mitigation strategy.

Contract structures

• Project contracts (integration): milestone-based, revenue recognised over time, generating contract assets. Lumpy and timing-sensitive - which is exactly why Q1 FY2026 was seasonally soft and Q2 FY2026 rebounded sharply on project revenue recognition.
• Purchase orders (equipment supply): transactional, delivery-based, fast cash conversion.
• Multi-year supply contracts (reagents, consumables): the Kedah award runs four years, 15 June 2026 to 14 June 2030. Predictable.
• Subscriptions (PACS, MEAMS, EaaS): recurring, multi-year. The KPJ PACS deal is explicitly subscription-based.
• Service contracts: annual or multi-year, attached to installed machines.

Trade receivables averaged around 55 days collection in FY2025. The order book of RM246.9m as at 31 July 2026 is described by management as providing earnings visibility over three to four years.

5. Competitive landscape

The structure of the industry

Malaysian medical device distribution has three distinct tiers, and LAC Med competes against a different set in each.

Tier 1 - the principals themselves. Siemens Healthineers, GE HealthCare, Canon Medical and Fujifilm operate direct Malaysian subsidiaries and sell major imaging systems straight to large hospital groups. They are simultaneously LAC Med's competitors and the template for its own existential risk: Philips or Samsung could, in principle, do the same.

Tier 2 - regional and multinational distributors. Transmedic, established 1980 and now part of EBOS Group's MedTech division, operates across Singapore, Malaysia, Thailand, Indonesia, Hong Kong, the Philippines and Vietnam. DKSH runs healthcare distribution across the region, with a separately listed Malaysian arm. These are better-capitalised, multi-country operators.

Tier 3 - Malaysian specialists. Antah Healthcare Group (established 1962, with bumiputera tendering support for government hospital supply), Medi-Life (M) Sdn Bhd, UMediC Group, BCM Alliance and dozens of smaller players. Around 41 active medical device distributors operate in Malaysia.

LAC Med sits in tier 3 by ownership and scale, but competes in tier 1 and 2 project work because of the Philips and Samsung rights.

Named competitors

Market caps are peer-size references at the dates shown and move continuously.

Where LAC Med wins and loses

Wins against the principals' direct subsidiaries when the job is a whole-project delivery inside a working hospital, when the customer is mid-sized rather than a flagship account, and when the incumbent service relationship already exists. A multinational's local subsidiary is optimised to sell machines; LAC Med is optimised to finish buildings.

Loses to them on the largest tenders at the largest hospital groups, where the principal will engage directly and where LAC Med's margin is simply an extra layer.

Wins against Transmedic and DKSH on Malaysian-specific ground: MOH tender history, concessionaire relationships, AELB licensing depth, and the fact that its brand rights for Philips and Samsung imaging in Malaysia are exclusive to it.

Loses to them on capital, on multi-country accounts, and if a brand owner decides to consolidate ASEAN distribution under one regional partner.

Wins against UMediC, BCM Alliance and the smaller specialists on everything requiring project capability and high-value brand rights. This is not really a fair fight - they do not bid for MRI suites.

Loses to them in commodity consumables, where price is the only variable and LAC Med has no manufacturing cost advantage.

Barriers to entry - how high, really

Genuinely high:

• Brand rights. The single hardest barrier. Philips and Samsung have appointed LAC Med; a new entrant cannot buy its way past that. This barrier protects LAC Med completely - right up until the day it protects someone else instead.
• AELB and MDA licensing for ionising radiation and medical device establishment. Slow, continuing, and attached to installations.
• Installed base. Roughly 2,600 machines generating replacement and service incumbency that a new entrant has no path to.
• Tender prequalification. Track record with MOH and concessionaires takes years to build.

Lower than they look:

• Capital. The business is asset-light - 85 employees, no manufacturing. EaaS changes this, but the core distribution business could be replicated cheaply if the brand rights were available.
• Technical labour. Field service engineers are hireable. The Deputy CEO's own career path, per the annual report - through Pharmaniaga, IDS Services and GE Healthcare - illustrates how mobile this talent pool is.

The honest verdict on the moat

The moat is almost entirely borrowed. LAC Med's defensibility rests on distributorship agreements it does not own, cannot force the renewal of, and which the prospectus states carry no guaranteed renewal even on full performance of obligations. The 46% ultrasound share is a share of somebody else's product.

What the company genuinely owns is the installed base, the licensing infrastructure, the service network and the customer relationships. That is real, and it is what a principal would have to replicate to go direct. But it is an execution moat, not a structural one, and it does not earn the language of a franchise.

The interesting question is whether the strategic pivot changes this. A PACS platform running across 30 KPJ hospitals, and a MEAMS software layer sitting on top of a hospital's asset fleet, are owned positions in a way that a Philips distributorship never is. That is the real reason the software push matters - not because software carries a higher margin, though it does, but because it is the first asset in this business that belongs to LAC Med.

Structural shifts underway

• Digitalisation mandate. Malaysia is targeting digitalised clinics by 2027 and hospitals by 2029. This advantages a distributor with ICT origins and disadvantages pure equipment dealers.
• Capex to opex migration. Hospitals increasingly prefer EaaS and instrument placement over outright purchase. This favours players with balance sheet capacity and penalises thinly capitalised distributors.
• AI entering radiology workflow. annalise.ai and AIRS Medical represent a new software layer. Whoever controls the imaging platform controls where the AI gets deployed.
• Consolidation of regional distribution. EBOS acquiring Transmedic is the template. Principals increasingly prefer fewer, larger regional partners - which is a slow-moving threat to single-country distributors.

6. Industry

What drives demand

Government health spending. Malaysian government health expenditure grew at a 10.2% CAGR between 2020 and 2024, and Ministry of Health procurement specifically grew at a 40.1% CAGR to RM453m in 2024 (Tradeview IPO note). Budget 2026 raised the Health Ministry allocation to RM46.5bn from RM45.3bn in 2025, including RM755m specifically to replace outdated equipment and procure new advanced tools, RM1.2bn to upgrade and maintain public hospitals and clinics, and RM100m for district hospital ward upgrades (The Star, 10 Oct 2025). That RM755m line is, quite directly, LAC Med's addressable public-sector opportunity for the year.

Demographics. Malaysia reached aged-nation status in 2021, with the 65-plus population growing at a 5.0% CAGR. Older populations consume diagnostic imaging at multiples of younger ones. Non-communicable disease prevalence is high, with approximately 2.3 million Malaysian adults carrying three NCDs simultaneously - a population that requires repeated imaging and laboratory testing rather than one-off treatment.

Private hospital capacity expansion. Malaysia is targeting RM12bn in medical tourism revenue by 2030, up from RM2.72bn in 2024, under the Malaysia Year of Medical Tourism 2026 initiative. Medical tourists select on facilities, which drives private hospital groups to invest in visible high-end imaging.

Technology replacement cycle. Imaging equipment has an economic life of roughly seven to ten years. With ~2,600 units installed, LAC Med has a structural replacement pipeline independent of market growth.

Industry size and growth

The Malaysian medical devices market is estimated at approximately USD 3.2bn, growing at roughly 8-9% CAGR through 2030, driven by government modernisation and demand for advanced diagnostics. Independent market research for the IPO was prepared by Vital Factor Consulting, which is the source of LAC Med's stated product-category shares: 46% in ultrasound machines, 11% in MRI, 6% in radiographic equipment.

Indonesia, the expansion market, has 2,710 general hospitals, 518 specialised hospitals and over 20,600 private clinics, with 65-plus at 7.6% of population (21.6 million people). The CEO has characterised Indonesia as roughly ten times Malaysia's population and eight times its market size.

Position in the supply chain

LAC Med occupies the middle. Manufacturing happens in the Netherlands, South Korea, the United States, Germany and Japan. LAC Med provides import, regulatory clearance, physical integration, commissioning, training, service and consumable supply. It captures the local value-added layer and none of the manufacturing margin.

There is essentially no import substitution dynamic here in LAC Med's favour, and it would be dishonest to claim one. High-end imaging equipment is not manufactured in Malaysia and will not be. Malaysia does have a substantial medical device contract manufacturing sector - gloves, catheters, orthopaedic components - but that is a different industry that competes with LAC Med's consumables suppliers rather than supporting LAC Med. The company will remain an importer, which means it will remain FX-exposed.

Regulatory environment

Three regimes matter:

1. Medical Device Act 2012 and the Medical Device Authority (MDA). Establishment licensing for importers and distributors; registration of each device. Continuing obligation, and a real barrier.
2. Atomic Energy Licensing Board (AELB). Licensing for ionising radiation equipment - X-ray, CT, fluoroscopy, angiography. Applies per installation, covering shielding adequacy, operator certification and periodic inspection.
3. Indonesian Ministry of Health registration for the PT Fairmed operation - a separate and slower process, and a genuine gating factor on how fast Indonesia can scale.

Government procurement policy also shapes the market structure: hospital support services concessionaires hold regional contracts for public hospitals, which means the concessionaire, not the hospital, is frequently LAC Med's contracting counterparty.

Cyclicality

Moderately cyclical with a strong intra-year seasonal pattern, and the two should not be confused.

The seasonal pattern is pronounced: Malaysian government budget cycles cluster awards, and Q1 is consistently the weakest quarter because the year's procurement decisions have not yet been made. LAC Med's Q1 FY2026 was described in exactly these terms - soft on "slower first-quarter award cycles tied to budget timing and capital expenditure schedules" - and Q2 FY2026 rebounded hard on project revenue recognition. This is calendar mechanics, not deterioration.

The cyclical pattern is gentler than most capital goods. Healthcare demand is inelastic; a fiscal squeeze defers hospital equipment purchases rather than cancelling them, and deferral creates pent-up replacement demand. Private hospital capex is more cyclical than public, tracking medical tourism flows and patient volumes. The consumables and service layer is close to acyclical, which is a further argument for the recurring-revenue pivot.

Tailwinds and headwinds

Tailwinds: rising government health allocation with a specific equipment replacement line item; aged-nation demographics; medical tourism ambition; the 2027/2029 digitalisation mandate; capex-to-opex preference favouring EaaS providers; Indonesia's scale.

Headwinds: ringgit volatility against USD, EUR and KRW on an import-dependent cost base; principals' ongoing incentive to disintermediate distributors; regional consolidation of distribution rights; price-driven public tender competition; and the possibility that health budget growth slows - Budget 2026's increase was smaller in percentage terms than prior years, and at least one health policy publication characterised it as health spending growth slowing.

7. Growth triggers

Sourced from the six management communication events listed at the top of this report. No earnings call transcripts exist for this company; each item below is attributed to the specific disclosure it came from.

• Kedah pathology reagent contract, four years, up to RM78.9m. LAC Medical Supplies accepted a letter of award from a healthcare concessionaire to supply reagents and related items for pathology chemistry tests to 10 Ministry of Health hospitals in Kedah, running 15 June 2026 to 14 June 2030, under an instrument placement arrangement. (Announced 15-16 June 2026; reported in the Q2 FY2026 results, 19 Aug 2026)

• Order book of RM246.9m as at 31 July 2026, which management states provides earnings visibility for the next three to four years. This is up from RM216.7m as at 15 February 2026. (Q2 FY2026 results, 19 Aug 2026; prior figure from FY2025 results, Feb 2026)

• Tender book expanded to RM769.8m as at 31 July 2026, from RM690.9m at 30 April 2026 and RM584m previously. Against a historical tender success rate of 25-30%, management frames this as the replenishment engine. (Q2 FY2026 results, 19 Aug 2026; repeated theme across FY2025 results, Q1 FY2026 and Q2 FY2026)

• KPJ Healthcare enterprise PACS rollout across 30 hospitals, subscription-based, full implementation targeted within 24 months of the 26 August 2025 signing - so completing around August 2027. The Philips enterprise imaging platform connects KPJ's hospitals on a single imaging platform and integrates with the KPJ Care patient application. (Announced 26 Aug 2025; carried forward in the FY2025 Annual Report, April 2026)

• Indonesia branch offices in Sumatra, Surabaya and Kalimantan during 2026-2027, funded from the RM8m IPO allocation, building on the Jakarta base operating since July 2025. (IPO prospectus and briefings, Nov-Dec 2025; restated in the FY2025 Annual Report, April 2026 - repeated across at least three disclosures)

  "a long-term build rather than a fast grab"

  The CEO's own framing, noting Indonesia's population is roughly ten times and its market roughly eight times Malaysia's. (The Edge, December 2025)

• Exclusive Alpinion ultrasound distributorship for Indonesia, carrying an existing 800-unit installed base. This is an entry with a service and consumables annuity already attached rather than a cold start. (IPO briefings, Nov-Dec 2025; FY2025 Annual Report, April 2026)

• EaaS scaling from the September 2025 billing start. RM8m of IPO proceeds allocated jointly to EaaS and MEAMS development. At listing the model was described as under 5% of revenue. (IPO briefings, Nov-Dec 2025)

  "Leasing is purely a financing mechanism. Under our model, we go on a risk-sharing, outcome-based partnership."

  (Liew Yoon Poh, The Edge, December 2025)

• MEAMS software platform commercialisation via GoCloud Solutions - IoT integration, GPS asset tracking, predictive maintenance analytics and cloud asset management, positioned against Malaysia's digitalisation targets of clinics by 2027 and hospitals by 2029. (IPO prospectus, Nov 2025; FY2025 Annual Report, April 2026)

• New head office and warehouse facility, RM12m of IPO proceeds. Capacity for the enlarged eleven-brand inventory and the EaaS fleet. (IPO prospectus, Nov 2025)

• Cross-selling the nine brands added since 2023 across the existing 300-plus account base and ~2,600 installed units, including laboratory equipment expansion and AI/digital solution deployment. Management described this at IPO as opening an additional addressable market of roughly RM700m. (IPO briefings, Nov-Dec 2025; restated as a strategic pillar in the FY2025 Annual Report, April 2026)

• Scaling the existing business for earnings visibility named as the explicit next phase of strategy. (CEO interview, The Star, 14 Sep 2026)

Trigger summary

8. Key risks

1. Distributorship dependency - the risk that defines the company

Mechanism. Philips and Samsung together contributed between 80.4% and 93.6% of group revenue across FY2022-FY2024. LAC Med holds these rights under agreements that, per the prospectus, contain no guaranteed renewal. The company is required to obtain written consent before distributing competing brands, which limits its ability to hedge. If Philips or Samsung declined to renew, appointed a second distributor, consolidated ASEAN distribution regionally, or established a direct Malaysian sales operation, a large fraction of revenue would be structurally impaired - not cyclically reduced.

The prospectus states the position without softening it:

"There is no guarantee that these distributorship agreements will be renewed, even if we fulfil all obligations, as renewal is at the discretion of the respective brand owners."

Calibration. Low probability in any given year, catastrophic if it happens. The relationships are 13 and 9 years old and appear healthy - the KPJ PACS win was a Philips platform, which is evidence of deepening rather than weakening. But "low annual probability of a business-ending event" compounds badly over a long holding period, and the precedent exists within the company's own history: the GE Healthcare distributorship expired in 2019. Management's response - two brands to eleven since 2023 - is the correct mitigation and is explicitly framed that way in the annual report's risk section. It has not yet meaningfully reduced the concentration, because the nine new brands are still small.

2. Working capital absorption, worsening as the model shifts

Mechanism. Three things consume cash simultaneously. Integration projects recognise revenue over time, creating contract assets - which rose to RM49.9m at 31 December 2025, a more-than-fifteen-fold increase in one year. Trade receivables run around 55 days. And both instrument placement and EaaS require LAC Med to buy the equipment and place it at the customer, recovering the outlay over four years or more.

The direction is unambiguous: the segment growing fastest (integration, +48.6% in FY2025) is the most working-capital intensive, and the two new business models both convert what used to be a cash sale into a receivable stream that LAC Med funds. Growth here consumes cash rather than generating it.

Calibration. High probability, moderate drag. This does not break the business; it constrains how fast it can grow without borrowing. Gearing improved sharply post-IPO, so there is headroom. But the IPO cash is finite and a portion is already committed to the Indonesia build and the new warehouse.

3. EaaS economics are thin and carry residual risk

Mechanism. The disclosed EaaS model finances equipment at roughly 4-6% and targets approximately a 10% IRR. That is a spread of a few hundred basis points on an asset LAC Med owns for the lease term. Three things can compress it: a rise in Malaysian borrowing costs, a hospital defaulting mid-term, or equipment residual value falling faster than assumed - a real risk when AI software can extend the useful life of an installed MRI while simultaneously making newer hardware more attractive.

Calibration. Moderate probability, moderate impact while EaaS remains under 5% of revenue. The risk scales directly with the strategy's success, which is an uncomfortable property. It deserves watching precisely as the model grows.

4. Customer concentration compounded by non-recurring revenue

Mechanism. With top-five customers estimated at around 68% of revenue and 97.8-98.3% of revenue non-recurring, a single large hospital group deferring its capital cycle removes revenue with nothing underneath to catch it. This is not a hypothetical - Q1 FY2026 was soft for exactly this structural reason, with management citing slower award cycles tied to budget timing.

Calibration. High probability of recurrence as a quarterly volatility driver, moderate as a sustained threat. The Kedah contract and the KPJ PACS subscription are the first meaningful pieces of ballast against it.

5. Foreign exchange on an import-only cost base

Mechanism. Every unit of equipment is imported and paid for in USD, EUR or KRW. Every contract is priced and settled in ringgit. On a project bid, the currency exposure runs from tender submission to delivery - often more than a year. Ringgit weakness between those two points compresses the project margin directly, and the integration segment's already-thin gross margin has the least room to absorb it.

Calibration. High probability, moderate impact. This is a standing feature of the business model, not an event. The Tradeview note lists it as a named risk, and the integration segment's margin profile is where it shows up.

6. Indonesia execution

Mechanism. PT Fairmed operates with roughly 20 people from a rented Jakarta office in a market with 2,710 general hospitals spread across an archipelago. It requires separate Indonesian Ministry of Health device registration, separate distribution relationships, and separate service infrastructure. The planned Sumatra, Surabaya and Kalimantan branches are a real fixed-cost build with an uncertain revenue ramp. Alpinion's 800-unit installed base helps, but one mid-tier ultrasound brand is a narrow platform on which to build a national presence.

Calibration. Moderate probability of disappointment, low-to-moderate impact - Indonesia was framed at IPO as contributing roughly 5% of group revenue in FY2026, so failure would be a growth disappointment rather than a solvency event. The CEO's own "long-term build rather than a fast grab" framing is a pre-emptive expectation reset, and reading it that way is fair.

7. Margin mix dilution

Mechanism. The lowest-margin segment (integration) grew 48.6% in FY2025 while the middle-margin segment (equipment supply) declined 40.4%. Group revenue can therefore grow while group profitability falls, purely on mix. The highest-margin segment is growing fastest in percentage terms but from only 12% of revenue, so it cannot yet offset the drag.

Calibration. High probability, moderate impact. This is arithmetic, not a risk event. The entire recurring-revenue strategy is the answer, and the answer needs several years.

8. Key-person and governance concentration

Mechanism. Two brothers - Liew Yoon Kit as Chairman and Liew Yoon Poh as Group CEO - plus co-founder Chan Yue Mun and substantial shareholder Giam Teck Eng, together control a large majority of the company. The operating history, the principal relationships and the tender track record are personally held. The organisation is 85 people. The board carries three independent directors (Dato' Ng Wan Peng as Senior Independent, Goh Teck Hong and Lim Su May), and the audit and nomination committees are independently chaired, which is the appropriate structure - but a controlling family block means minority shareholders are along for whatever ride the controllers choose.

Calibration. Low probability of acute failure, high structural significance. The professionalisation is visible and recent: a Deputy CEO, Chief Commercial Officer, Chief People Officer and SVP of Service Operations were all appointed in March 2025, with a CFO appointed October 2024, immediately ahead of the IPO. That is a deliberate build-out of a second management layer, and it is the right response.

9. Reporting opacity and a short public record

Mechanism. H1 FY2026 profit fell year on year, and management attributed the decline to a one-off RM6m revenue adjustment from the prior year related to the MFRS framework transition (The Sun, Aug 2026). The explanation is plausible and specific. But a company nine months into its listed life, with no earnings call, no analyst Q&A, and a first earnings decline explained by an accounting base effect, gives an outside investor very little independent means of verification. The risk is not that the explanation is wrong - it is that no mechanism currently exists to test it.

Calibration. Moderate probability of recurrence, low individual impact, but it is the reason Section 9 below cannot yet reach a confident verdict.

9. Walk the talk

The six management communication events used: IPO prospectus and launch briefing (14 Nov 2025); listing day statements (10 Dec 2025); FY2025 results (mid-Feb 2026); Annual Report 2025 (April 2026); Q1 FY2026 results (18 May 2026); Q2 FY2026 results (19 Aug 2026). Plus a CEO interview in The Star on 14 September 2026 - six days before this report.

To state it plainly: there are no earnings call transcripts for this company, and there is not yet enough elapsed time to judge management credibility properly. What follows is an honest assessment of nine months of public record. Anyone presenting it as a settled verdict on management quality is overreaching.

Starting at the prospectus, November 2025

The IPO document made four checkable commitments. One: expand the brand portfolio and cross-sell it - the two-to-eleven expansion was already complete at listing, so this was a delivered fact presented as a plan, which is a mild but real piece of framing. Two: build recurring revenue through EaaS, MEAMS and consumables, with RM8m of proceeds allocated. Three: enter Indonesia via PT Fairmed with branches in Sumatra, Surabaya and Kalimantan across 2026-2027, with RM8m allocated. Four: a dividend policy of at least 30% of group profit after tax.

The prospectus also disclosed the uncomfortable things without burying them: the Philips and Samsung concentration, the absence of renewal guarantees, and the 97.8-98.3% non-recurring revenue figure. Disclosing the number that most damages your own equity story is a genuine credibility marker, and LAC Med did it.

Listing day, December 2025

The CEO called the listing "a pivotal moment" and set out the 58% hospital coverage, 217-of-373 position and the 300-plus account base. No specific financial guidance was issued. The Indonesia framing was deliberately modest - "a long-term build rather than a fast grab" - which is an unusual thing for a CEO to say in the week of a listing, when the incentive runs entirely the other way. It reads as expectation management rather than promotion, and it earns credit.

FY2025 results, February 2026

The first reported period as a public company. Management disclosed an order book of RM216.7m as at 15 February 2026 and stated that more than 60% would be recognised within FY2026. The tender book stood at RM584m against a stated 25-30% historical win rate.

The recurring-revenue segment grew 61.2% in FY2025 - the fastest of the three segments, and directly supportive of the strategy articulated ten weeks earlier at the IPO. The integration segment grew 48.6%. Both are real, and both were achieved before the IPO money was deployed.

The less comfortable line in the same set of results: the medical equipment supply segment - the middle-margin one - declined 40.4%, and I could not find a management explanation for it in any disclosure I was able to read. A 40% decline in a segment representing a quarter of revenue is the kind of item that would be the first question on an earnings call. There is no earnings call.

Annual Report 2025, April 2026

Three strategic pillars were restated in the same terms used at the IPO: strengthen Malaysian market share across the eleven brands; increase recurring revenue via MEAMS, EaaS, consumables and service; expand Indonesia. Consistency of strategic message across four months and three documents is worth noting - management is not reframing the story quarter to quarter.

The annual report also confirmed the dividend commitment was met. FY2025 dividends totalled approximately 35% of profit after tax, against a policy floor of 30%.

Q1 FY2026 results, 18 May 2026

The first soft quarter. The order book was disclosed at RM199m, down from the RM216.7m reported three months earlier, and management attributed the quarter to "slower first-quarter award cycles tied to budget timing and capital expenditure schedules."

Two observations. First, the explanation is structurally sound - Malaysian government procurement genuinely clusters later in the year, and this is a known seasonal feature, not an excuse invented for the occasion. Second, and more to management's credit, they disclosed a declining order book rather than quietly omitting the metric. It would have been easy to report the tender book (which had risen to RM690.9m from RM584m) and stay silent on the order book. They reported both.

Q2 FY2026 results, 19 August 2026

The recovery quarter, driven by higher revenue recognition from ongoing integration projects. The order book recovered to RM246.9m as at 31 July 2026, now above the February figure, and the tender book expanded again to RM769.8m. The Kedah contract had been secured in June.

The awkward item: H1 FY2026 profit declined year on year, attributed to a one-off RM6m prior-year revenue adjustment relating to the MFRS framework transition. Management's forward language was "cautiously optimistic" for the year to 31 December 2026 - which, notably, is not an upgrade despite the order book and tender book both hitting new highs. A management team inclined to overpromise would have paired a record tender book with a confident outlook statement. This one did not.

The promise-versus-outcome record

Assessment

The record is short, consistent, and so far honest - with a real transparency gap around the new business models.

What management has done well: disclosed uncomfortable numbers at IPO that hurt their own story; kept a single strategic message across four disclosures without drifting; reported a falling order book rather than hiding it behind a rising tender book; met the dividend commitment above the policy floor; declined to upgrade the outlook on a quarter that would have supported one.

What is missing: EaaS and MEAMS revenue contribution, and Indonesia's contribution, have not been quantified in any post-listing disclosure I could locate. Those three items are the growth story. They were quantified at IPO - under 5%, and roughly 5% respectively - and they have gone quiet since. That is the single thing an investor should press management on, and the absence of an earnings call is precisely what makes it hard to press.

Verdict: no broken promises, but no completed promise cycle either. Management has not yet had to explain away a real miss - the H1 profit decline was attributed to a prior-year accounting base effect, which is the first "explain-away" moment and a mild one. The genuine tests arrive in 2027: whether the KPJ PACS rollout completes on the 24-month schedule, whether the Indonesian branches open in the stated window, and whether the recurring-revenue share of the mix is materially higher than 12%. Judge them then, not now.

10. Shareholder friendliness index

Dividends. LAC Med has a stated policy of distributing at least 30% of group profit after tax. A three-year DPS series is not meaningful here: the company listed on 10 December 2025, so FY2023 and FY2024 distributions were private-company payments to four shareholders on a different share count, and I could not verify those amounts. For the one full year as a listed entity, FY2025 total dividends were approximately 35% of profit after tax, comprising a pre-IPO interim of RM5.0m (paid 28 July 2025, before the current 400m share count existed) and a final dividend of 0.65 sen per share, ex-date 26 May 2026, paid 15 June 2026. That clears the policy floor. No FY2026 interim dividend had been declared as at 19 August 2026. There is no dividend trend to assess yet - there is one datapoint, and it met the commitment.

Buybacks and dilution. MoatMap's database records zero buybacks in the trailing ~90 days (since 22 June 2026). Extending the search beyond that window: LAC Med has been listed only since 10 December 2025, so the maximum possible buyback history is roughly nine months, and I found no share buyback mandate authorised or executed at any point since listing in Bursa announcements, financial news or the FY2025 annual report's capital management disclosures. There is therefore no authorised-versus-repurchased comparison to make - the programme does not exist. On dilution: shares outstanding went from 325.8m pre-IPO to 400m at listing, a 22.8% increase from the 74.2m new shares issued in the public issue. That was the IPO itself, not creeping dilution. I found no employee share option scheme or ongoing issuance programme, and the count has been stable at 400m since December 2025. Separately, three of the four founding shareholders - Liew Yoon Poh, Liew Yoon Kit and Giam Teck Eng - sold part of their holdings in the IPO offer-for-sale, raising RM22.5m for themselves; Chan Yue Mun's stake moved only by dilution, implying he did not sell.

Verdict: Neutral, leaning toward Returns Capital. A 35% payout in the first reported year against a 30% policy floor is a real commitment honoured, but one year of listed dividend history and no buyback programme is not yet enough evidence to classify this as a capital-returning company.

11. Insider activities

Source: MoatMap cross-market disclosure database (market: MY), data current as at 18 September 2026. Bursa Malaysia's announcements portal is bot-gated, and MoatMap's nightly scrape of the exchange is the canonical source for recent Malaysian insider dealing. The filings correspond to Bursa "Changes in Director's Interest (Section 219 CA 2016)" and "Changes in Substantial Shareholder's Interest" announcements.

Recent transactions - last 12 months

(Bursa Changes in Director's Interest / Changes in Substantial Shareholder's Interest, 2026-05-29)

Aggregate: 3 buys, 0 sells, 0 other transactions in the trailing 12 months.

Buys - reading the signal

Three separate insiders bought on the same day, and no insider has sold a share in the open market since listing. Cluster buying across a Chairman, a Group CEO and an unaffiliated substantial shareholder is structurally the most reliable insider signal there is, because it is hard to construct three independent non-informational reasons for the same-day decision.

But the sizes demand honest calibration, and inflating them would be a disservice. These are small purchases. RM70,200 for the Chairman and RM13,572 for the Group CEO are modest sums against holdings that run to tens of millions of shares each - Liew Yoon Poh held roughly 20.9% of the company post-IPO and Liew Yoon Kit roughly 16.4%. In percentage-of-outstanding terms, all three transactions together amount to roughly 0.05% of the company. For the Group CEO in particular, a RM13,572 purchase is a fraction of what an executive at this level would earn in a month.

The honest read is that this is a signalling purchase, not a conviction purchase. The insiders were telling the market something with the fact of buying together and with the timing - three days after the 26 May 2026 ex-date for the maiden final dividend, and in the window following a Q1 the market had read as soft. That is a considered gesture. It is not the same thing as insiders backing up the truck, and it should not be presented as one.

Two secondary observations. First, Giam Teck Eng's purchase is arguably the most interesting: he is a substantial shareholder without a board seat, already heavily exposed, with no executive compensation to reinvest, and he bought the largest share count of the three. Second, none of the three is a first-time buyer with no history - these are founding shareholders, so "the CEO bought for the first time in five years" framing does not apply. The company has only existed publicly for nine months.

Sells

There are none. No open-market sales by any director or substantial shareholder in the trailing 12 months. This is worth stating explicitly because there was an obvious opportunity to sell: three of the four founders had already monetised part of their stakes in the IPO offer-for-sale in December 2025, raising RM22.5m between them, and post-listing moratoriums on Main Market promoters typically expire around the six-month mark. The window opened and nobody used it.

Net assessment

Insiders are unambiguously net buyers, with zero offsetting sales. The activity is broad rather than concentrated - three different people, including one with no board role - and it is directionally clean.

The qualifier is size. Roughly RM84,000 of disclosed value plus one unpriced 100,000-share purchase is a small absolute commitment from people who collectively control a majority of the equity. A reader should weight the direction and the clustering heavily and the magnitude lightly.

Plain-language read: mildly bullish. The cluster and the complete absence of selling after a lock-up expiry are genuine positives, and the fact that the founders who sold into the IPO subsequently bought back in the open market is a coherent and favourable pattern. But the sums involved are symbolic, and calling this anything stronger than mildly bullish would be reading more into three small tickets than they can bear.

12. Scenarios

Bull case

The pivot works, and LAC Med stops being a distributor.

It begins with the KPJ rollout. By late 2027 the Philips enterprise PACS is live across all thirty KPJ hospitals, billing monthly, integrated with the KPJ Care patient application - and critically, it is the platform through which annalise.ai and SwiftMR get deployed to radiologists in every one of those hospitals. LAC Med is no longer the company that delivered a project; it is the company inside the workflow. KPJ becomes the proof case that sells the same architecture to Sunway, to Columbia Asia, to the university hospitals. Each win is a multi-year subscription rather than a tender to be re-fought.

Underneath that, the reagent and consumables annuity compounds quietly. The Kedah contract runs cleanly to 2030 and, because LAC Med executes it well, the concessionaire routes further state pathology packages the same way. Instrument placement turns out to be the right structural answer to a Ministry of Health with a growing equipment replacement line and a constrained capital budget. The related-products segment - 12% of revenue in FY2025 - is a materially larger share of the mix by 2029, and because it carries roughly three times the integration segment's gross margin, group profitability rises even in years when project revenue is flat.

Indonesia turns from a cost centre into a second engine. The Sumatra, Surabaya and Kalimantan branches open on schedule, Alpinion's 800 installed ultrasound units become a service and consumables base rather than just a distributorship, and PT Fairmed starts winning the same kind of integration work in Jakarta that LAC Med wins in Klang Valley. The addressable hospital count is seven times Malaysia's, and LAC Med is early.

And the concentration problem solves itself by dilution. The nine brands added since 2023 - Stryker in neurovascular, Abbott in diagnostics, Bayer in contrast, Baxter in care equipment - grow into real contributors, so that by the end of the decade Philips and Samsung are a large minority of revenue rather than nearly all of it. When the renewal conversations come, LAC Med is negotiating from a position it did not have in 2019.

Base case

Management delivers roughly what it has guided, and the transition happens slowly.

The order book converts on schedule. The tender book keeps growing and the 25-30% win rate holds, so replenishment roughly matches burn and the backlog oscillates in a widening band - RM200m to RM300m - with the seasonal Q1 dip recurring every year and being explained, correctly, every year as budget timing. Revenue grows, driven mostly by the integration segment, because that is where the tenders are. Group profitability stays roughly flat or drifts modestly, because the segment doing the growing is the lowest-margin one and the recurring segment, while growing faster in percentage terms, is too small to move the average quickly.

The KPJ PACS rollout completes, perhaps a few months later than the 24-month target, because thirty-hospital IT deployments generally do. It does not immediately produce a second contract of similar scale. EaaS grows from under 5% of revenue to something still modest, constrained by the working capital it consumes and by hospital treasurers who remain more comfortable owning assets than renting them. MEAMS finds real customers against the 2027 and 2029 digitalisation deadlines, but as a useful adjacent product rather than a platform.

Indonesia contributes something in the mid single digits of group revenue and stays there for several years - a genuine option that has not yet been exercised, absorbing cash and management attention while the Jakarta team learns a market that is harder than it looks from Petaling Jaya.

Philips and Samsung renew. The concentration persists but does not detonate. The dividend continues at or slightly above the 30% policy floor, funded comfortably by a business that converts a reasonable share of profit to cash once the contract-asset build stabilises. The company ends up roughly where it started strategically - a well-run Malaysian medical device distributor with a growing software attachment and an Indonesian toehold - which, given where it started, is a perfectly respectable outcome.

Bear case

The borrowed moat gets called in.

The mechanism is not dramatic and would not arrive as a single announcement. Philips consolidates ASEAN distribution - perhaps following the same logic that took Transmedic into EBOS - and appoints a regional partner covering Malaysia, Singapore, Thailand and Indonesia under one agreement. LAC Med's Malaysian exclusivity becomes a shared arrangement, then a transitional one. The prospectus warned that renewal sits entirely at the brand owner's discretion, and discretion is exercised for the brand owner's reasons, not the distributor's. The nine newer brands are not yet big enough to fill the hole, and building them to that scale takes years the company does not have once the clock starts.

Even short of that, a slower version does damage. The integration segment keeps growing as a share of the mix while the middle-margin equipment segment keeps shrinking - the FY2025 pattern, where one grew 48.6% and the other fell 40.4%, simply persisting. Revenue rises and profitability falls, year after year, on mix alone. Simultaneously the contract-asset balance keeps climbing as more revenue is recognised over time rather than on delivery, EaaS and instrument placement consume more equipment funded off the balance sheet, and the IPO cash - already committed across Indonesia, the new warehouse and EaaS development - runs down. The company borrows to fund growth in its lowest-margin activity, and a 4-6% cost of funds against a targeted 10% IRR stops looking like a spread and starts looking like a risk.

Then the demand side softens. Malaysian health budget growth slows further from the already-moderated Budget 2026 increase; a large private hospital group defers a capital cycle; a concessionaire contract changes hands and the incumbent relationship goes with it. Because 97.8-98.3% of revenue was non-recurring and the recurring layer is still only a small share of the mix, there is nothing underneath to catch the fall. Two or three soft quarters arrive in succession, each explained through a channel that allows no follow-up questions, because there is no earnings call.

And Indonesia, in this version, is the wound rather than the hedge: three branch offices opened into a market that required more registration time, more local relationships and more service infrastructure than a twenty-person Jakarta team could build, carrying fixed costs against revenue that never reached the 5% of group that was indicated at listing.

None of these individually breaks the company. The bear case is that they are correlated - a margin mix drifting the wrong way, a balance sheet absorbing more working capital, a new geography consuming cash, and a principal relationship that was always someone else's to end.